Overview
- At 36 weeks, 31.7% of patients on the combination met the primary outcome of at least a 50% reduction in disease activity plus at least 10% weight loss, versus 0.8% on Taltz alone.
- The combination achieved ACR50 in 33.5% of participants compared with 20.4% on monotherapy, meeting key secondary endpoints for superiority.
- TOGETHER-PsA enrolled 271 adults with active psoriatic arthritis who were overweight or obese and had at least one additional weight-related condition in an open-label Phase 3b design.
- Lilly reported gastrointestinal events such as nausea, diarrhea and constipation as the most common side effects, generally described as mild to moderate.
- Lilly says this is the first controlled study to test an incretin with a PsA biologic, with full datasets pending and related psoriasis trial topline results expected in the first half of 2026.